Heron Therapeutics, Inc. (HRTX) Coverage Initiated at Mizuho
Research analysts at Mizuho assumed coverage on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Tuesday. The brokerage set a “buy” rating and a $28.00 price target on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 71.78% from the company’s previous close.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, July 12th. Aegis reiterated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Heron Therapeutics in a report on Monday, June 26th. ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $30.20.
Shares of Heron Therapeutics (NASDAQ HRTX) opened at 16.00 on Tuesday. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.85. The firm has a 50-day moving average of $15.81 and a 200 day moving average of $14.97. The company’s market capitalization is $866.21 million.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. On average, equities research analysts expect that Heron Therapeutics will post ($3.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/heron-therapeutics-inc-hrtx-coverage-initiated-at-mizuho.html.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Tang Capital Management LLC boosted its holdings in Heron Therapeutics by 39.7% during the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the last quarter. FMR LLC boosted its holdings in Heron Therapeutics by 36.7% during the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the last quarter. Janus Henderson Group PLC bought a new position in Heron Therapeutics during the second quarter worth about $78,134,000. Janus Capital Management LLC boosted its holdings in Heron Therapeutics by 20.2% during the first quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock worth $82,524,000 after buying an additional 925,948 shares during the last quarter. Finally, Broadfin Capital LLC boosted its holdings in Heron Therapeutics by 26.9% during the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock worth $74,211,000 after buying an additional 1,047,816 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.